In this Court of Appeal case ([2025] EWCA Civ 374), Safestand successfully appealed a High Court ruling that their designs were invalid.

In the recent decision T1553/22, the Board of Appeal considered whether methods of producing a human-porcine chimera and a chimeric animal itself are excluded from patentability under Article 53(a) EPC...

MP: Jodie, thank you for agreeing to take part in our conversation series which highlights and celebrates the incredible people at the heart of our organisation. I am excited to hear your insights as

Ever since the Supreme Court shook up the patent landscape in the UK with their decision in Actavis v Eli Lilly there has been an open question regarding how the newly enlarged patent scope which encompasses equivalents ...

When discussing my profession, particularly with those outside of intellectual property, I often mention that I am involved with food related inventions.

I'm delighted to be joined today by Jonathan Pratt, a Partner at Boult specialising in engineering and designs, and Angela McCleave HR Director. Jonathan Pratt has an active part in overseeing the educational needs...

The Enlarged Board of Appeal has now issued its decision in G 1/25, the referral regarding amendment of the description when inconsistencies arise after amendment of the claims.

The European Union Intellectual Property Office (EUIPO) is implementing significant changes to EU design registration procedures, introducing dynamic and animated representation formats alongside traditional static views. These reforms will fundamentally alter how design applicants protect their intellectual property, from expanded visual documentation options to streamlined invalidity proceedings and new amendment mechanisms for registered designs.

After years of uncertainty in the timeline of the Unified Patent Court (UPC), it has just been announced that Germany will ratify the UPC Agreement on 17th February 2023.

Dr Nina White, Partner, European Patent Attorney, Registered UPC Representative in the biotechnology and life sciences field at Boult in conversation with Dr Michelle Pratt.

evtana® (cabazitaxel) in combination with prednisone or prednisolone is approved for the treatment of patients with hormone-refractory metastatic prostate cancer (mCRPC)...

One of the more unique, and often debated, aspects of prosecution before the EPO is the requirement that the description and claims must be in conformity. Historically, these changes...

Not quite eight months have gone by since, at a snap, the High Court judgement in favour of Emotional Perception AI Ltd upended the patentability (or otherwise) of artificial neural networks (ANNs) in the UK.

The Unified Patent Court (UPC) has recently released its latest update on the case load of the Court* since it commenced operations in June 2023.

The Enlarged Board of Appeal's recent decision in consolidated cases G1/22 and G2/22 has greatly simplified the consideration of priority entitlement at the EPO.

I have written previously an article about the difficulties Lego has faced in securing Registered European Union Designs (REUDs) before the EU Intellectual Property Office (EUIPO).

Since the Unified Patent Court opened on 1 June 2023, one of the more interesting legal questions which has been considered is the matter of jurisdictional competence. Following on from our comparison of the EPO and UPC’s approaches to inventive step (available here) and as the dust begins to settle on some of the early decisions, it is a good time to reflect on the early decisions of the UPC in relation to jurisdiction and to compare the UPC with the EPO in this regard.

An investigation is underway after multiple sclerosis patients in the UK reported adverse effects following a switch from the originator medicine Tysabri to its biosimilar Tyruko. Despite regulatory approval confirming no clinically meaningful differences between the two natalizumab-based treatments, subtle variations in manufacturing processes, formulation buffers, and molecular characteristics may explain why some patients have experienced worsening symptoms or side effects.

In two recent decisions, O/0878/25 and O/0876/25, applications for invalidity were made for registered designs based on Amazon listings where the Amazon web page states that the product...